Evaluation of therapeutic adherence to antihyperglycemic agents in patients with type 2 diabetes

##plugins.themes.academic_pro.article.sidebar##

Published Jan 2, 2025
https://doi.org/10.62438/tunismed.v103i1.5265
Download
pdf
Vol. 103 No. 1 (2025): Tunis Med Jan 2025

##plugins.themes.academic_pro.article.main##

Bilel Ben Amor
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Faculty of Medicine of Monastir, University of Monastir, Tunisia
Hanene Sayadi
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Faculty of Medicine of Monastir, University of Monastir, Tunisia
Ines Bayar
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Faculty of Medicine of Monastir, University of Monastir, Tunisia
https://orcid.org/0000-0001-7992-2355
Aicha Ghachem
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Tunisia
Ekram Hajji
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Faculty of Medicine of Monastir, University of Monastir, Tunisia
Hela Marmouch
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Faculty of Medicine of Monastir, University of Monastir, Tunisia
Ines Khochtali
Department of Endocrinology and Internal Medicine , Fattouma Bourguiba Hospital, Monastir. Faculty of Medicine of Monastir, University of Monastir, Tunisia

Abstract

Introduction-Aim: Type 2 diabetes (T2D) is a major public health problem. To succeed its management and prevent its complications, good therapeutic adherence must be ensured. The objectives of our work were to estimate the prevalence of poor therapeutic adherence in our patients and to identify its associated factors.


Methods: we conducted a cross-sectional, single-center study that included type 2 diabetic outpatients. Therapeutic adherence to antihyperglycemic agents was assessed by the 8-item Morisky Medication Adherence Scale (MMAS-8).


Results: We included 172 patients. The mean age was 59.7±9.5 years. The mean duration of T2D was 11.7±8.5 years. Glycemic targets were achieved in 35% of patients with a mean HbA1c of 8.5±1.8%. The prevalence of poor adherence was 66.1%. Factors associated with poor adherence were age <65 years (p=0.007), low educational level (p=0.026), diabetes follow-up < 2 consultations/year (p=0.004), non-practice of self-monitoring of blood glucose (p=0.008) and ignorance of glycemic targets (p=0.001).


Conclusion: Poor adherence affects a large proportion of our T2D patients. In order to improve it, therapeutic adherence should be an important theme in the education of patient

Keywords:

Type 2 diabetes mellitus, therapeutic adherence, antihyperglycemic agents

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Magliano DJ, Boyko EJ, IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021 [cited 2023 Apr 15]. (IDF Diabetes Atlas). Available from: http://www.ncbi.nlm.nih.gov/books/NBK581934/
  2. Scheen AJ, Giet D. Non-observance thérapeutique: causes, conséquences, solutions. Rev Médicale Liège. 2010 Jun;65(5–6):239–45.
  3. Sabaté E, World Health Organization, editors. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. 198 p.
  4. Azharuddin M, Adil M, Sharma M, Gyawali B. A systematic review and meta-analysis of non-adherence to anti-diabetic medication: Evidence from low- and middle-income countries. Int J Clin Pract. 2021 Nov;75(11):e14717.
  5. Badr W, Ghammam R, Ammar A, Ben Fredj S, Maatoug J, Ghannem H. L’observance thérapeutique chez le diabétique de type 2. Ann Endocrinol. 2018 Sep 1;79(4):476.
  6. Lajili O, Zouaoui C, Benchhida A, Menjli S, Ouertani H. Évaluation de l’observance thérapeutique chez les patients diabétiques de type 2. Ann Endocrinol. 2021 Oct 1;82(5):477.
  7. Mehrez A, Sebai I, Naceur K, Zribi S, Saafi E, Hkiri G, et al. Évaluation de l’observance thérapeutique du patient diabétique. Ann Endocrinol. 2020 Sep 1;81:444.
  8. good_practice_-_self-monitoring_blood_glucose_type_2_diabetes.pdf [Internet]. [cited 2024 Sep 3]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2011-12/good_practice_-_self-monitoring_blood_glucose_type_2_diabetes.pdf
  9. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic Targets: Standards of Care in Diabetes—2023. Diabetes Care. 2023 Jan;46(Suppl 1):S97–110.
  10. Ashur ST, Shamsuddin K, Shah SA, Bosseri S, Morisky DE. Reliability and known-group validity of the Arabic version of the 8-item Morisky Medication Adherence Scale among type 2 diabetes mellitus patients. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 2015 Dec 13;21(10):722–8.
  11. Achouri MY, Tounsi F, Messaoud M, Senoussaoui A, Ben Abdelaziz A. Prévalence de la mauvaise observance thérapeutique chez les diabétiques de type 2 en Afrique du Nord. Revue systématique et méta-analyse. Tunis Médicale. 2021 Oct;99(10):932–45.
  12. Jaam M, Ibrahim MIM, Kheir N, Awaisu A. Factors associated with medication adherence among patients with diabetes in the Middle East and North Africa region: A systematic mixed studies review. Diabetes Res Clin Pract. 2017 Jul;129:1–15.
  13. Evans M, Engberg S, Faurby M, Fernandes JDDR, Hudson P, Polonsky W. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes Obes Metab. 2022;24(3):377–90.
  14. Tiv M, Viel JF, Mauny F, Eschwège E, Weill A, Fournier C, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study. PloS One. 2012;7(3):e32412.
  15. Kirkman MS, Rowan-Martin MT, Levin R, Fonseca VA, Schmittdiel JA, Herman WH, et al. Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database. Diabetes Care. 2015 Jan 8;38(4):604–9.
  16. Chew BH, Hassan NH, Sherina MS. Determinants of medication adherence among adults with type 2 diabetes mellitus in three Malaysian public health clinics: a cross-sectional study. Patient Prefer Adherence. 2015 May 6;9:639–48.
  17. Kassahun T, Gesesew H, Mwanri L, Eshetie T. Diabetes related knowledge, self-care behaviours and adherence to medications among diabetic patients in Southwest Ethiopia: a cross-sectional survey. BMC Endocr Disord. 2016 May 31;16:28.
  18. Aloudah NM, Scott NW, Aljadhey HS, Araujo-Soares V, Alrubeaan KA, Watson MC. Medication adherence among patients with Type 2 diabetes: A mixed methods study. Puebla I, editor. PLOS ONE. 2018 Dec 11;13(12):e0207583.
  19. Benrazavy L, Khalooei A. Medication Adherence and its Predictors in Type 2 Diabetic Patients Referring to Urban Primary Health Care Centers in Kerman City, Southeastern Iran. Shiraz E-Med J [Internet]. 2019 [cited 2023 Apr 14];20(7). Available from: https://brieflands.com/articles/semj-84746.html#abstract
  20. Alqarni AM, Alrahbeni T, Qarni AA, Qarni HMA. Adherence to diabetes medication among diabetic patients in the Bisha governorate of Saudi Arabia – a cross-sectional survey. Patient Prefer Adherence. 2018 Dec 24;13:63–71.
  21. Z J, N MK. Medication Adherence and Diabetes Self-Care Activities Among Patients With Type 2 Diabetes Mellitus. Value Health Reg Issues [Internet]. 2019 May [cited 2023 May 8];18. Available from: https://pubmed.ncbi.nlm.nih.gov/30419448/
  22. al majed. adhernce of type 2 diabetic patients to their treatment. Kuwait medical journal.
  23. Koprulu F, Bader RJK, Hassan N, Abduelkarem AR, Mahmood DA. Evaluation of Adherence to Diabetic Treatment in Northern Region of United Arab Emirates. Trop J Pharm Res. 2014 Sep 16;13(6):989–95.
  24. Jarab AS, Almrayat R, Alqudah S, Thehairat E, Mukattash TL, Khdour M, et al. Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes. Int J Clin Pharm. 2014 Aug;36(4):725–33.
  25. Khattab MS, Aboifotouh MA, Khan MY, Humaidi MA, al-Kaldi YM. Compliance and control of diabetes in a family practice setting, Saudi Arabia. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 1999 Jul;5(4):755–65.
  26. Sinha S, A T. Adherence to treatment in type 2 diabetes mellitus patients receiving multiple drug therapy. Int J Res Med Sci. 2019 May 29;7(6):2084–8.
  27. Jimmy B, Jose J, Al-Hinai ZA, Wadair IK, Al-Amri GH. Adherence to Medications among Type 2 Diabetes Mellitus Patients in Three Districts of Al Dakhliyah Governorate, Oman. Sultan Qaboos Univ Med J. 2014 May;14(2):e231–5.
  28. Heissam K, Abuamer Z, El-Dahshan N. Patterns and obstacles to oral antidiabetic medications adherence among type 2 diabetics in Ismailia, Egypt: a cross section study. Pan Afr Med J. 2015 Feb 25;20:177.
  29. Thapar R, Holla R, Kumar N, Aithal S, Karkera S, Rao C, et al. Factors influencing adherence to anti-diabetes medications among type 2 diabetes patients attending tertiary care hospitals in Mangaluru. Clin Epidemiol Glob Health. 2020 Dec 1;8(4):1089–93.
  30. Piragine E, Petri D, Martelli A, Calderone V, Lucenteforte E. Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. J Clin Med. 2023 Jan;12(5):1981.